dornase alfa; nebulized recombinant human DNase (Pulmozyme, rhDNAse, nrhDNAse)
Jump to navigation
Jump to search
Introduction
Tradename: Pulmozyme.
Indications
- cystic fibrosis (CF)
- to reduce frequency of respiratory tract infections that require antibiotics
- to improve pulmonary function
- early treatment of benefit (protective effect)[3]
- role in increased longevity of patients with CF[5]
Dosage
Storage
2-8 degrees C, protect from light
Adverse effects
- common (> 10%)
- alteration of voice
- hoarseness
- rash
- chest pain
- pharyngitis
- less common (1-10%)
Mechanism of action
- Aerosolized recombinant human DNAse 1.
More general terms
References
- ↑ The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- ↑ Kaiser Permanente Northern California Regional Drug Formulary, 1998
- ↑ 3.0 3.1 3.2 Journal Watch 21(24):198, 2001 Suri R et al Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet 358:1316, 2001 PMID: https://www.ncbi.nlm.nih.gov/pubmed/11684212
- ↑ 4.0 4.1 Journal Watch 22(3):20, 2002 Quan JM et al, A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 139:813, 2001 PMID: https://www.ncbi.nlm.nih.gov/pubmed/11743506
- ↑ 5.0 5.1 George PM et al. Improved survival at low lung function in cystic fibrosis: Cohort study from 1990 to 2007. BMJ 2011 Feb 28; 342:d1008 PMID: https://www.ncbi.nlm.nih.gov/pubmed/21357627
- ↑ Pulmozyme; note=Clinical information on Pulmozyme http://www.pulmozyme.com/patient/0_0_index.jsp